Table 8 The combined synergizing effects of Venetoclax on cellular apoptosis
Cancer | Cell Type | Combined | Apoptosis | Ref |
|---|---|---|---|---|
ALL | LOUCY cell line | doxorubicin, l-asparaginase, and dexamethasone | – | [302] |
AML | Primary cells and U937 | daunorubicin or cytarabine | – | [303] |
AML | KOPT-K1 | S63845 | synergized | [304] |
AML | MV4–11 and MOLM-13, KG-1a, U937, and THP-1 | triptolide | synergized | [305] |
AML | Jurkat and Molt4 | gemcitabine | synergized | [306] |
AML | Molm14 and OCI-AML3 | VS-4718 | – | [307] |
AML/MDS/CMML | Ex-vivo samples | 5-azacytidine | – | [112] |
Breast | 23 T Xenografts and MCF7 | tamoxifen, AZD8055 | – | [308] |
CML | KCL22 | imatinib | sensitized | [309] |
CRC | Xenograft and RKO cell line | LZT-106 | synergized | [310] |
Diffuse BCL and FL | Cell lines and TMD8 xenograft model | ibrutinib | synergized | [311] |
Leukemia, Lymphoma | SU-DHL-4, OCI-Ly1 199R, SC-1199R and BCl and FL primary samples | A-1592668 and analogue A-1467729 | synergized | [312] |
Nasopharyngeal | CNE-2, 5-8F | S63845 | synergized | [293] |
MM | OPM2, H929 | THZ1 | synergized | [313] |
MM | U266, KMS11, OPM2, RPMI8226 and KMS28-PE | flavopiridol | synergized | [314] |
Pancreatic | MIA Paca-2 xenograft | gemcitabine | – | [301] |
Soft Tissue Sarcoma | Rhabdomyosarcoma, SW982 (synovial sarcoma) cells or primary cells | bortezomib | synergized | [315] |